What are the functions and effects of Belzutifan?

Belzutifan is a new type of hypoxia-inducible factor-2α (HIF-2α) inhibitor. Its unique targeting mechanism has attracted widespread attention in the field of cancer treatment in recent years. As a drug approved by the US FDA for the treatment of solid tumors related to von Hippel-Lindau (VHL) disease, the mechanism of action of besetivan is different from traditional chemotherapy or immunotherapy, and acts more directly on the hypoxic environment regulatory pathways that tumor cells rely on to survive. The drug blocks the transcriptional activity of HIF-2α, thereby affecting the expression of genes related to it, thereby inhibiting tumor angiogenesis, cell proliferation and metabolic adaptation. This mechanism allows it to exhibit good therapeutic potential in a variety of highly vascularized solid tumors.

A key efficacy of bezotivan lies in its significant inhibitory effect onVHL-related solid tumors such as clear cell renal cell carcinoma, pancreatic neuroendocrine tumors and retinal hemangiomas. These tumors result in continuous activation of the HIF-2α signaling pathway due to VHL gene mutations, thereby promoting the growth of tumor cells in a hypoxic environment. Bestivan can effectively block this pathway, cutting off the tumor's dependence on oxygen metabolism from the source, reducing the tumor growth rate while also inhibiting the formation of new blood vessels, giving it the ability to stabilize the disease and delay progression. In recent years, the FDA has approved bezutivan for the treatment of a variety of non-metastatic tumors related to VHL syndrome, which is based on its unique molecular mechanism and clinical durable response rate.

In May 2025, the U.S. FDA further approved bezutivan for the treatment of adults and children over 12 years old with locally advanced, unresectable or metastatic pheochromocytoma and paraganglioma (PPGL), marking a key step for the drug in the treatment of neuroendocrine tumors. This type of tumor also has a high degree of vascular dependence and metabolic activity, and the central role of the HIF-2α signaling axis in its occurrence and development makes the efficacy of besettivan in this indication supported by molecular mechanisms. Especially in patients with locally advanced or metastatic PPGL for whom traditional surgery or radiotherapy has limited effect, bezutivan, as an oral targeted drug, provides a new solution for disease control.

In addition to directly inhibiting tumor progression, bezutivan also shows potential in controlling accompanying symptoms. For example, in catecholamine-secreting tumors such as PPGL, patients are often accompanied by severe hypertension. By controlling tumor activity, bezutivan can help relieve symptoms and reduce dependence on antihypertensive drugs, thereby improving patients' quality of life. In addition, bestivan is an oral preparation, and its once-daily administration improves patients' treatment compliance and facilitates long-term treatment, especially in patients who cannot tolerate frequent intravenous treatment.

Overall, the mechanism of action of besetifan is cutting-edge, and it plays an important role in inhibitingThe efficacy of HIF-2α-mediated hypoxia pathway is currently difficult to replace by other anti-tumor drugs. Its main efficacy is not only reflected in tumor volume reduction and progression control, but also in systemic regulation of the tumor microenvironment and comprehensive relief of symptoms.

Reference materials:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-pheochromocytoma-or-paraganglioma